Join the club for FREE to access the whole archive and other member benefits.

New longevity startup MitoRx Therapeutics is developing mitochondria protective drugs

25-Apr-2022

Key points from article :

MitoRx Therapeutics aims to reverse mitochondrial dysfunction to halt progression of degenerative disease.

Secured seed funding to develop its mitochondrial-protective therapeutics.

Funds towards its pre-clinical proof-of-concept platform, research collaborations and partnerships.

According to Pitchbook, the company has raised around $2.1 million to date.

Complete reversal of loss-of strength in a C. elegans model of Duchenne muscular dystrophy.

Neuroprotection in a mammalian model of Alzheimer’s disease, through the restoration of sulphide-signalling.

Therapeutic pipeline of small molecule candidates for Duchenne muscular dystrophy (DMD), CBS-deficiency, and Huntington’s disease.

The company also claims to have programs in Alzheimer’s, Parkinson’s, sarcopenia, cancer cachexia, COPD and IPF.

“We are the first biotech to address dysfunction of sulphide-signalling, a fundamental part of life’s energy systems,” - Jon Rees, CEO of MitoRx.

Targeting age-related diseases, the company's pre-clinical compounds to progress to the clinic

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Company Representative

CEO and co-founder at MitoRx Therapeutics

Company

Pre-clinical stage rare disease biotech company aiming to develop treatments for degenerative diseases